Urogenital mycoplasmosis and pregnancy
Urogenital mycoplasmas – Ureaplasma urealyticum, Ureaplasma parvum and Mycoplasma hominis have long been considered commensals of human urogenital microflora.Põder A., Haldre M.
Objective. To clarify whether these bacteria could cause or be associated with various obstetric complications.
Materials and methods. Data from epidemiological studies published on this topic were included.
Results. Epidemiologic studies have found high prevalence of Ureaplasma spp. and M. hominis among otherwise healthy population. On the other hand, U.urealyticum, U. parvum and M. hominis have increasingly been linked to adverse pregnancy outcomes such as spontaneous pre-term labor, pre-term premature rupture of fetal membranes, miscarriage, stillbirth and low birth weight. However, no convincing causal relationship has been shown. Studies have shown that antibiotics resistance is on the rise and differs considerably by regions.
Conclusion. Screening of asymptomatic patients for M. hominis, U. urealyticum and U. parvum is currently still not indicated.
Keywords
urogenital mycoplasmosys
Ureaplasma urealyticum
Ureaplasma parvum
Mycoplasma hominis
pregnancy
Supplementary Materials
- Table 1. Prevalence of urogenital mycoplasmas
- Table 2. Results of studies on association of ureaplasmas with obstetric complications
- Table 3. Percentage of resistant strains, sample size in brackets
References
1. Tibaldi C., Cappello N., Latino M.A., Masuelli G., Marini S., Benedetto C. Vaginal and endocervical microorganisms in symptomatic and asymptomatic non-pregnant females: risk factors and rates of occurrence. Clin. Microbiol. Infect. 2009; 15(7): 670-9.
2. Verteramo R., Patella A., Calzolari E., Recine N., Marcone V., Osborn J. et al. An epidemiological survey of Mycoplasma hominis and Ureaplasma urealyticum in gynaecological outpatients, Rome, Italy. Epidemiol. Infect. 2013; 141(12):2650-7.
3. Zdrodowska-Stefanow B., Kłosowska W.M., Ostaszewska-Puchalska I., Bułhak-Kozioł V., Kotowicz B. Ureaplasma urealyticum and Mycoplasma hominis infection in women with urogenital diseases. Adv. Med. Sci. 2006; 51: 250-3.
4. Kacerovský M., Pavlovský M., Tosner J. Preterm premature rupture of the membranes and genital mycoplasmas. Acta Med. (Hradec Kralove). 2009; 52(3): 117-20.
5. Pignanelli S., Pulcrano G., Schiavone P., Iula V.D., Catania M.R. In vitro antimicrobial susceptibility of Mycoplasma hominis genital isolates. Indian J. Dermatol. Venereol. Leprol. 2015; 81(3): 286-8.
6. Redelinghuys M.J., Ehlers M.M., Dreyer A.W., Lombaard H.A., Kock M.M. Antimicrobial susceptibility patterns of Ureaplasma species and Mycoplasma hominis in pregnant women. BMC Infect. Dis. 2014; 14: 171.
7. Ouzounova-Raykova V.V., Markovska R., Mizgova G., Mitov I.G. Detection of the sexually transmissible genital mycoplasmas by polymerase chain reaction in women. Sex. Health. 2011; 8(3): 445-6.
8. Baka S., Kouskouni E., Antonopoulou S., Sioutis D., Papakonstantinou M., Hassiakos D. et al. Prevalence of Ureaplasma urealyticum and Mycoplasma hominis in women with chronic urinary symptoms. Urology. 2009; 74(1): 62-6.
9. Naaber P., Ratnik K., Raud K., Sepp S., Põder A. Relevance of molecular complex diagnostics for genital tract infections. Eesti Arst. 2014;93(8): 450-5.
10. Ahmadi A., Khodabandehloo M., Ramazanzadeh R., Farhadifar F., Nikkhoo B., Soofizade N., Rezaii M. Association between Ureaplasma urealyticum endocervical infection and spontaneous abortion. Iran. J. Microbiol. 2014;6(6): 392-7.
11. Mitsunari M., Yoshida S., Deura I., Horie S., Tsukihara S., Harada T. et al. Cervical Ureaplasma urealyticum colonization might be associated with increased incidence of preterm delivery in pregnant women without prophlogistic microorganisms on routine examination. J. Obstet. Gynaecol. Res. 200; 31(1): 16-21.
12. Bayraktar M.R., Ozerol I.H., Gucluer N., Celik O. Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women. Int. J. Infect. Dis. 2010; 14(2): e90-5.
13. Witt A., Berger A., Gruber C.J., Petricevic L., Apfalter P., Worda C., Husslein P. Increased intrauterine frequency of Ureaplasma urealyticum in women with preterm labor and preterm premature rupture of the membranes and subsequent cesarean delivery. Am. J. Obstet. Gynecol. 2005; 193(5):1663-9.
14. Kataoka S., Yamada T., Chou K., Nishida R., Morikawa M., Minami M. et al. Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy. J. Clin. Microbiol. 2006; 44(1): 51-5.
15. Kasprzykowska U., Elias J., Elias M., Mączyńska B., Sobieszczańska B.M. Colonization of the lower urogenital tract with Ureaplasma parvum can cause asymptomatic infection of the upper reproductive system in women: a preliminary study. Arch. Gynecol. Obstet. 2014; 289(5): 1129-34.
16. 16. Kasper D.C., Mechtler T.P., Reischer G.H., Witt A., Langgartner M., Pollak A. et al. The bacterial load of Ureaplasma parvum in amniotic fluid is correlated with an increased intrauterine inflammatory response. Diagn. Microbiol. Infect. Dis. 2010; 67(2): 117-21.
17. Abele-Horn M., Scholz M., Wolff C., Kolben M. High-density vaginal Ureaplasma urealyticum colonization as a risk factor for chorioamnionitis and preterm delivery. Acta Obstet. Gynecol. Scand. 2000; 79(11): 973-8.
18. Raynes Greenow C.H., Roberts C.L., Bell J.C., Peat B., Gilbert G.L., Parker S. Antibiotics for ureaplasma in the vagina in pregnancy. Cochrane Database Syst. Rev. 2011; (9): CD003767.
19. Donders G.G., Van Bulck B., Caudron J., Londers L., Vereecken A., Spitz B. Relationship of bacterial vaginosis and mycoplasmas to the risk of spontaneous abortion. Am. J. Obstet. Gynecol. 2000; 183(2): 431-7.
20. Leli C., Meucci M., Vento S., D’Alò F., Farinelli S., Perito S. et al. Microbial and vaginal determinants influencing Mycoplasma hominis and Ureaplasma urealyticum genital colonization in a population of female patients. Infez. Med. 2013; 21(3): 201-6.
21. Manhart L.E. Mycoplasma genitalium: An emergent sexually transmitted disease? Infect. Dis. Clin. North Am. 2013; 27(4): 779-92.
22. Manhart L.E., Broad J.M., Golden M.R. Mycoplasma genitalium: Should we treat and how? Clin. Infect. Dis. 2011; 53(Suppl. 3): S129-42.
23. Hitti J., Garcia P., Totten P., Paul K., Astete S., Holmes K.K. Correlates of cervical Mycoplasma genitalium and risk of preterm birth among Peruvian women. Sex. Transm. Dis. 2010; 37(2): 81-5.
24. Edwards R.K., Ferguson R.J., Reyes L., Brown M., Theriaque D.W., Duff P. Assessing the relationship between preterm delivery and various microorganisms recovered from the lower genital tract. J. Matern. Fetal Neonatal Med. 2006; 19(6): 357-63.
25. Weinstein S.A., Stiles B.G. Recent perspectives in the diagnosis and evidence-based treatment of Mycoplasma genitalium. Expert Rev. Anti Infect. Ther. 2012; 10(4): 487-99.
26. Kokkayil P., Dhawan B. Ureaplasma: Current perspectives. Indian J. Med. Microbiol. 2015; 33(2): 205-14.
27. Machado Ldel P., Molinari M.A., dos Santos L., de Cordova C.M. Performance of four commercial kits for laboratory diagnosis of urogenital mollicute infection. Can. J. Microbiol. 2014; 60(9): 613-7.
28. Shipitsyna E., Savicheva A., Solokovskiy E., Ballard R.C., Domeika M., Unemo M., Jensen J.S.; EE SRH Network. Guidelines for the laboratory diagnosis of mycoplasma genitalium infections in East European countries. Acta Derm. Venereol. 2010; 90(5): 461-7.
29. Aguilera-Arreola M.G., González-Cardel A.M., Tenorio A.M., Curiel-Quesada E., Castro-Escarpulli G. Highly specific and efficient primers for in-house multiplex PCR detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma hominis and Ureaplasma urealyticum. BMC Res. Notes. 2014; 7: 433.
30. Lillis R.A., Nsuami M.J., Myers L., Martin D.H. Utility of urine, vaginal, cervical, and rectal specimens for detection of Mycoplasma genitalium in women. J. Clin. Microbiol. 2011; 49(5): 1990-2.
31. Pónyai K., Mihalik N., Ostorházi E., Farkas B., Párducz L., Marschalkó M. et al. Incidence and antibiotic susceptibility of genital mycoplasmas in sexually active individuals in Hungary. Eur. J. Clin. Microbiol. Infect. Dis. 2013; 32(11): 1423-6.
32. De Francesco M.A., Caracciolo S., Bonfanti C., Manca N. Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years. J. Infect. Chemother. 2013; 19(4): 621-7.
33. Krausse R., Schubert S. In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years. Clin. Microbiol. Infect. 2010; 16(11):1649-55.
34. Jensen J.S., Cusini M., Gomberg M., Moi H. 2016 European guideline on Mycoplasma genitalium infections. J. Eur. Acad. Dermatol. Venereol. 2016; 30(10): 1650-6. Available at: http://www.iusti.org/regions/Europe/pdf/2016/IUSTI_mycoplasma_guidelines2016.pdf Accessed on 29 July 2016.
35. Renaudin H., Tully J.G., Bebear C. In vitro susceptibilities of Mycoplasma genitalium to antibiotics. Antimicrob. Agents Chemother. 1992; 36(4): 870-2.
36. Guschin A., Ryzhikh P., Rumyantseva T., Gomberg M., Unemo M. Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin. BMC Infect. Dis. 2015; 15: 40.
37. Ye G., Jiang Z., Wang M., Huang J., Jin G., Lu S. The resistance analysis of Ureaplasma urealyticum and Mycoplasma hominis in female reproductive tract specimens. Cell Biochem. Biophys. 2014; 68(1): 207-10.
38. Koh E., Kim S., Kim I.S., Maeng K.Y., Lee S.A. Antimicrobial susceptibilities of Ureaplasma urealyticum and Mycoplasma hominis in pregnant women. Korean J. Clin. Microbiol. 2009; 12(4): 159-62.
39. Zhanel G.G., Dueck M., Hoban D.J., Vercaigne L.M., Embil J.M., Gin A.S., Karlowsky J.A. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001; 61(4): 443-98.
40. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 2002; 34(4): 482-92.
Received 15.05.2017
Accepted 23.06.2017
About the Authors
Airi Põder, MD, Dermatologist-Venerologist, Tartu University Hospital, Dermatology Clinic. Raja 31, Tartu 50417, Estonia. Tel.: +372 50 58 949. E-mail: Airi.Poder@std.eeMadli Haldre, MD, Physician, Tartu Univerisity Clinics Foundation. Puusepa 8, Tartu, Estonia. Tel.: +372 52 29 543. E-mail: Madli.Haldre@gmail.ee
For citations: Põder A., Haldre M. Urogenital mycoplasmosis and pregnancy. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (12): 5-15. (in Russian)
https://dx.doi.org/10.18565/aig.2017.12.5-15
Similar Articles
